Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
5 results
Search Results
Item Lung Cancer in Turkey(2022) Cangir, Ayten Kayi; Yumuk, Perran Fulden; Sak, Serpil Dizbay; Akyurek, Serap; Eralp, Yesim; Yilmaz, Ulku; Selek, Ugur; Eroglu, Atilla; Tatli, Ali Murat; Dincbas, Fazilet Oner; Kilickap, Saadettin; Sendur, Mehmet Ali Nahit; Dilektasli, Asli Gorek; Bozcuk, Hakan Sat; Ozkok, Serdar; Oztop, Ilhan; Topkan, Erkan; Dilege, Sukru; Kaya, Akin; Demirkazik, Ahmet; 36192076Item Turkish Thoracic Society Experts Consensus Report: Recommendations for Pulmonary Function Tests During and After COVID 19 Pandemic(2020) Gemicioglu, Bilun; Borekci, Sermin; Dilektasli, Asli Gorek; Ulubay, Gaye; Azap, Ozlem; Saryal, Sevgi; 0000-0002-3171-8926; 0000-0003-2478-9985; 32584237; AAK-4089-2021; AAB-5064-2021The recommendation of conducting pulmonary function tests (PFTs) from different societies during and after the coronavirus disease (COVID-19) pandemic was rated by the experts of the Turkish Thoracic Society (TTS) and presented as the TTS experts consensus report. Information about the topic has been provided. Globally, as of mid-May 2020, there have been over 4.4 million confirmed cases of COVID-19. There are two main routes of transmission of COVID-19: respiratory droplets and contact transmission. PFTs are non-invasive tests that are commonly performed in routine assessment and follow-up of patients in the pulmonology units. However, PFTs may generate aerosols and require sharing common surfaces. With regard to the high prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the community, PFTs should not be performed routinely in confirmed or suspected patients with COVID-19 during the pandemic. Because of the risk of human-to-human transmission of COVID-19, PFTs should be restricted to a small patient population with selected indications. Triage for COVID-19 should be performed prior to testing. Only essential PFTs such as spirometry, diffusion capacity of the lungs for carbon monoxide (DLCO), arterial blood gas analysis, or pulse oximetry should be performed in the selected cases. Tests should be scheduled to allow sufficient time for donning and doffing of the technical personnel with the full personal protective equipment (PPE) (gown, a filtering respirator mask, goggles or full-face shield, and disposable gloves), ventilation of the room, and application of post-test cleaning and disinfection procedures of the equipment and the testing room.Item Turkish Thoracic Society Consensus Report: Interpretation of Spirometry(2019) Ulubay, Gaye; Dilektasli, Asli Gorek; Borekci, Sermin; Yildiz, Oznur; Kiyan, Esen; Gemicioglu, Bilun; Saryal, Sevgi; 0000-0003-2478-9985; 30664428; AAB-5064-2021Currently, the criteria for applying and evaluating spirometer measurements have been defined by American and European Respiratory Societies. Several pulmonary function test laboratories in Turkey as well as in the world use these standards. However, different interpretation results are observed in different pulmonary function test laboratories. This report is prepared to provide a basis for a standardized asssessment in our pulmonary function test in our country.Item Risk Assessment of Tuberculosis in Immunocompromised Patients A TBNET Study(2014) Dilektasli, Asli Gorek; 25303140Rationale: In the absence of active tuberculosis, a positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA) result defines latent infection with Mycobacterium tuberculosis, although test results may vary depending on immunodeficiency. Objectives: This study compared the performance of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability to identify those at risk for development of tuberculosis. Methods: Immunocompromised patients with HIV infection, chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell transplantation, and healthy control subjects were evaluated head-to-head by the TST, QuantiFERON-TB-Gold in-tube test (ELISA), and T-SPOT. TB test (enzyme-linked immunospot) at 17 centers in 11 European countries. Development of tuberculosis was assessed during follow-up. Measurements and Main Results: Frequencies of positive test results varied from 8.7 to 15.9% in HIV infection (n = 768), 25.3 to 30.6% in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2% in immunocompetent control subjects (n = 211). Eleven patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis during a median follow-up of 1.8 (interquartile range, 0.2-3.0) years. Six of the 11 patients had a negative or indeterminate test result in all three tests at the time of screening. Tuberculosis incidence was generally low, but higher in HIV-infected individuals with a positive TST (3.25 cases per 100 person-years) than with a positive ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 person-years). No cases of tuberculosis occurred in patients who received preventive chemotherapy. Conclusions: Among immunocompromised patients evaluated in this study, progression toward tuberculosis was highest in HIV-infected individuals and was poorly predicted by TST or IGRAs.Item Summary of Consensus Report on Preoperative Evaluation(2015) Ozkan, Metin; Kirkil, Gamze; Dilektasli, Asli Gorek; Sogut, Ayhan; Sertogullarindan, Bunyamin; Cetinkaya, Erdogan; Coskun, Funda; Ulubay, Gaye; Yuksel, Hasan; Sezer, Murat; Ozbudak, Omer; Ulasli, Sevinc Sarinc; Arslan, Sulhattin; Kovan, Tezay; 29404077